Navigation Links
Personalized molecular therapy shows promising results for people with advanced lung cancer
Date:12/9/2010

A new study shows that a combination of epigenetic therapy and molecular targeted therapy has promising results at combating advanced lung cancer according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is co-sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (ISLAC) and The University of Chicago.

Epigenetics therapy is an approach designed to control the expression of good and bad genes that influence the development of resistance to targeted therapies. This study, called ENCORE 401, was designed to evaluate whether entinostat, a novel epigenetic therapy that is given orally, can be used to delay or overcome the resistance to erlotinib in patients with advanced lung cancer.

This study was a randomized phase II placebo controlled clinical trial in advanced lung cancer examining whether entinostat in combination with erlotinib is better than erlotinib alone and whether it can be safely tolerated by patients. As part of the clinical trial, patients underwent an analysis of various tissue and blood biomarkers. The results demonstrated that patients with elevated E-cadherin (a molecular marker) who were administered entinostat in combination with erlotinib had a significantly improved overall survival as compared to patients treated with erlotinib alone. Approximately 40 percent of non-small cell lung cancer patients have elevated E-cadherin.

These findings highlight the importance of patient selection in defining treatment approaches in lung cancer and, if confirmed, could provide benefit to patients who have or develop resistance to current molecular targeted therapy.

"The results of ENCORE 401 identified a subset of lung cancer patients for whom the combination of epigenetic therapy, entinostat and molecular targeted therapy, erlotinib, achieved promising result
'/>"/>

Contact: Beth Bukata
bethb@astro.org
703-431-2332
American Society for Radiation Oncology
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Personalized vaccine for lymphoma patients extends disease-free survival by nearly 2 years
2. Personalized medicine: Tumor analysis reveals new opportunities for existing cancer drugs
3. New venture explores frontiers of personalized medicine
4. Personalized treatment may help some liver cancer patients
5. Perspectives on improving patient care: Genetics, personalized medicine, and behavioral intervention
6. Penn receives $12 million NIH grant to research personalized approach to smoking cessation
7. Personalized medicine: Molecular imaging predicts treatment success in many cancers
8. Pilot study supports adolescent diabetes patients through personalized text messages
9. Tumor target suggests personalized treatment for melanoma
10. Advances in personalized medicine take center stage
11. Myth Debunked: Baby Shower Gifts CAN Be Personalized Without Knowing Name Or Gender
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... Yisrayl Hawkins, Pastor at The House of ... light of the Ferguson, Missouri unrest. Yisrayl starts his letter ... explains why it has only increased. , He continues ... He says there is a very specific reason for mankind ... is a set of rules, or Laws that if followed ...
(Date:12/26/2014)... 2014 India Network Foundation, a non-profit ... USA, announced today a new version of “ EasySelect ... the right plan for their visiting parents. The technology ... the selection process when choosing an insurance plan by ... only a few clicks. Many elderly Asian Indian parents ...
(Date:12/25/2014)... December 26, 2014 The microscopy ... of 7.2% to reach $5,756.0 million by 2019. ... microscopy market. The electron microscopes product segment is ... forecast period. , Rising focus on nanotechnology, technological ... of the microscopy market. , Get Full Copy ...
(Date:12/25/2014)... Dallas, TX (PRWEB) December 26, 2014 ... Analysis to 2023” focuses on the current treatment landscape, ... colorectal cancer market. TS-1 is an anti-cancer drug which ... administered orally and is also used for treating gastric ... gimestat and otastat potassium. The drug was first approved ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 Recently, Dylan ... dresses, has excitedly released its collection of discounted prom ... to Percy, a senior spokesman of the company, the ... of this promotion is to expand the UK market. ... in several different colors, lengths, and styles: A-line strapless, ...
Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Pleads for Peace in Ferguson and Beyond in New Open Letter 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2
... MedCath Corporation,(Nasdaq: MDTH ) announced today ... strategic relationship with Solaris Health System of Edison, ... a new venture to manage the,catheterization laboratories of ... Muhlenberg Regional Medical Center. Solaris, local,cardiologists, and MedCath ...
... Seventy percent of,Americans would be more likely ... creation of a nationwide health information network (NHIN),according ... (NYSE: CSC ). The survey explores people,s ... (IT) during a,presidential election year., While a ...
... Nutrition,Inc. (OTC Bulletin Board: NTNI) http://www.naturalnutritioninc.com ... Connolly will discuss last,year,s record breaking results as ... hear the interview in its entirety, visit ... be accessed either by locating the,company,s ticker symbol ...
... Fla., Feb. 19 NewsMark Public Relations,today announced ... and,autism consultant Valerie Herskowitz to publicize the national ... the challenges of,autism and other developmental disabilities., ... the results of Valerie,s,extensive research into the latest ...
... GILBERT, Ariz., Feb. 18 The following was,released ... wait times? Ambulance diversion? Crowded,emergency departments? Reports and ... should expect longer emergency department wait times (in,excess ... that more than one,third of area hospitals were ...
... found more exchanges occurred when people were encouraged to ... Providing patients with e-mail access to their surgeon appears ... who use e-mail certainly would like to have e-mail ... study, published in the February issue of the ...
Cached Medicine News:Health News:MedCath Announces Venture With Two New Jersey Hospitals 2Health News:MedCath Announces Venture With Two New Jersey Hospitals 3Health News:Seven Out of 10 Americans Would Vote for a Presidential Candidate Who Supports a Nationwide Health Information Network, CSC Survey Says 2Health News:Seven Out of 10 Americans Would Vote for a Presidential Candidate Who Supports a Nationwide Health Information Network, CSC Survey Says 3Health News:Natural Nutrition CEO Tim Connolly to Appear on Wall Street.net 2Health News:Autism Consultant Valerie Herskowitz Retains NewsMark Public Relations to Herald the Autism Support Village and Launch of www.valerieherskowitz.com 2Health News:Gilbert Hospital Turns the Tables on the Flu 2Health News:E-mails Improve Patient-Surgeon Communication 2
(Date:12/24/2014)... 2014  Advanced Medical Isotope Corporation ("AMIC") (OTCQB: ADMD), ... the development of brachytherapy devices and medical isotopes ... it has filed a de novo ... for marketing clearance for its patented Y-90 RadioGel(TM) ... Food, Drug and Cosmetic Act (the "Act").  ...
(Date:12/24/2014)... , Dec. 23, 2014  Lockton Dunning Benefits, ... Lockton Companies, announced the addition of Vice President ... join Lockton Dunning,s Pharmacy Consulting team, Excelsior Solutions. ... relevant industry experience to the position.  Most recently, ... Sales at Diplomat Specialty Pharmacy, where she has ...
(Date:12/24/2014)... 23, 2014  Medical Science Liaisons play a large ... between the medical device industry and key stakeholders, the ... coming years as the device industry relies on them ... research by benchmarking firm, Best Practices, LLC, one area ... edge is by harnessing new technology to enable education. ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3Kim Foerster Joins Lockton Companies 2Role of Medical Science Liaisons Evolving in Medical Device Sector 2
... Spine, LLC, today announced that the InterPlate® C-Ti has been ... devices occurred in 2007, the C-Ti was the first system ... this most recent announcement, the C-Ti has now become the ... cervical plate as well. , RSB Spine Chief Executive Officer ...
... , MIAMI, Oct. 12 AvMed Health Plans ... all of its fully insured members. Co-pays, co-insurance and deductibles ... if they have a benefit plan that does not include ... well-being of our members and we want to ensure that ...
Cached Medicine Technology:AvMed Covers H1N1 Flu Vaccine For Members 2
... to adults, the entire series of time-tested ... of the needs of care providers and ... the accuracy. You can see it in ... the performance, year after year. Every Timeter® ...
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
Medicine Products: